Physician profile
Christopher David Hancock
NPI 1083289144
$3,696.70
in general payments reported to CMS, 2019-2025
30 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2024: $892 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $501.43 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $334.67 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $318.46 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $313.67 | 2024-2025 | |
| Pfizer INC. | $252.35 | 2024-2025 | |
| Lilly USA, LLC | $231.86 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Viatris Specialty LLC | $219.34 | 2025 | Yupelri |
| Amgen INC. | $164.43 | 2024-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.96 | 2025 | Caplyta |
| Lundbeck LLC | $140.33 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $139.03 | 2024-2025 | Gemtesa |
| Biogen, INC. | $119.55 | 2024-2025 | Skyclarys |
| Exact Sciences Corporation | $80.90 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $74.66 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $71.16 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.94 | 2025 | Jardiance |
| Almatica Pharma LLC | $48.70 | 2024-2025 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.20 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $37.74 | 2025 | Symbravo, Auvelity |
| Ironshore Pharmaceuticals INC. | $37.13 | 2024 | |
| Supernus Pharmaceuticals, INC. | $35.30 | 2025 | |
| Phathom Pharmaceuticals, INC. | $33.73 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $32.88 | 2024-2025 | Zoryve |
| Collegium Pharmaceutical, INC. | $23.17 | 2025 | Jornay Pm |
| Dexcom, INC. | $20.75 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $17.02 | 2024 | Xarelto |
| Corium, LLC | $16.33 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $15.39 | 2025 | Rexulti |
| Mylan Specialty L.P. | $13.75 | 2024 | Yupelri |
| Dynavax Technologies Corporation | $8.93 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.